322 related articles for article (PubMed ID: 7593436)
1. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
[TBL] [Abstract][Full Text] [Related]
2. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
3. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
4. Sandostatin LAR in acromegalic patients: a dose-range study.
Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
[TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
6. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
Stewart PM; Stewart SE; Clark PM; Sheppard MC
Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053
[TBL] [Abstract][Full Text] [Related]
8. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly].
Priou A; Levesque G; Simonetta C; Lancranjan I; Roger P; Jaquet P
Ann Endocrinol (Paris); 1995; 56(3):213-8. PubMed ID: 7677407
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
12. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
13. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.
Lancranjan I; Atkinson AB
Pituitary; 1999; 1(2):105-14. PubMed ID: 11081188
[TBL] [Abstract][Full Text] [Related]
14. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
15. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
16. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
[TBL] [Abstract][Full Text] [Related]
17. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
18. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
19. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
20. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]